Stock Scorecard

Stock Summary for Agios Pharmaceuticals Inc (AGIO) - $24.95 as of 12/23/2025 2:32:49 PM EST

Total Score

10 out of 30

Safety Score

30 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for AGIO

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for AGIO

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for AGIO

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for AGIO

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for AGIO (30 out of 100)

Stock Price Rating (Max of 10) 7
Historical Stock Price Rating (Max of 10) 8
Stock Price Trend (Max of 10) 2
Book Value (Max of 10) 7
Book Value to Price (Max of 10) 1
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 0
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 10
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) -10

Latest News for for AGIO

Alpha Thalassemia Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Genmedicn Biopharma Ltd., Bristol-Myers Squibb, Agios Pharma 12/22/2025 2:09:00 PM
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Average Recommendation of "Moderate Buy" from Brokerages 12/21/2025 8:09:00 AM
Agios Pharmaceuticals, Inc. Being Investigated on Behalf of Agios Pharmaceuticals, Inc. Investors. Contact Levi & Korsinsky For Details 12/19/2025 7:42:00 AM
Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? You May Have Been Affected by Fraud - Contact Levi & Korsinsky 12/17/2025 9:09:00 PM
Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? You May Have Been Affected by Fraud - Contact Levi & Korsinsky 12/17/2025 7:30:00 AM
Agios Pharmaceuticals, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - AGIO 12/15/2025 7:25:00 AM
Agios Pharmaceuticals, Inc. $AGIO Shares Purchased by Bellevue Group AG 12/13/2025 10:09:00 PM
Agios Pharmaceuticals, Inc. $AGIO Position Boosted by Boothbay Fund Management LLC 12/13/2025 9:08:00 AM
Armistice Capital LLC Has $38.85 Million Holdings in Agios Pharmaceuticals, Inc. $AGIO 12/12/2025 10:09:00 PM
Levi & Korsinsky Announces an Investigation on Behalf of Agios Pharmaceuticals, Inc. (AGIO) Shareholders Who May Have Been Affected by Fraud 12/12/2025 10:08:00 PM

Financial Details for AGIO

Company Overview
Ticker AGIO
Company Name Agios Pharmaceuticals Inc
Country N/A
Description Agios Pharmaceuticals, Inc. is a leading biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of innovative therapies for oncology and rare genetic disorders by targeting cellular metabolism. With a robust pipeline and a commitment to precision medicine, Agios leverages its deep expertise in metabolic pathways to deliver transformative treatments that aim to improve patient outcomes. The company is also known for its strategic collaborations, which bolster its research and development initiatives, highlighting its dedication to advancing scientific knowledge and optimizing therapeutic strategies in complex disease areas.
Sector Name HEALTHCARE
Industry Name BIOTECHNOLOGY
Most Recent Quarter 9/30/2025
Next Earnings Date 2/12/2026

Stock Price History
Last Day Price 24.95
Price 4 Years Ago 32.87
Last Day Price Updated 12/23/2025 2:32:49 PM EST
Last Day Volume 2,564,378
Average Daily Volume 2,146,832
52-Week High 46.00
52-Week Low 22.24
Last Price to 52 Week Low 12.19%

Valuation Measures
Trailing PE N/A
Industry PE 70.99
Sector PE 135.38
5-Year Average PE -4.29
Free Cash Flow Ratio 15.69
Industry Free Cash Flow Ratio 14.52
Sector Free Cash Flow Ratio 32.38
Current Ratio Most Recent Quarter 13.82
Total Cash Per Share 1.59
Book Value Per Share Most Recent Quarter 22.04
Price to Book Ratio 1.16
Industry Price to Book Ratio 64.08
Sector Price to Book Ratio 56.98
Price to Sales Ratio Twelve Trailing Months 32.20
Industry Price to Sales Ratio Twelve Trailing Months 22.22
Sector Price to Sales Ratio Twelve Trailing Months 16.53
Analyst Buy Ratings 7
Analyst Strong Buy Ratings 0

Share Statistics
Total Shares Outstanding 58,314,000
Market Capitalization 1,454,934,300
Institutional Ownership N/A

Dividends
Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement
Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth 291.35%
Reported EPS 12 Trailing Months -7.01
Reported EPS Past Year -5.26
Reported EPS Prior Year -6.35
Net Income Twelve Trailing Months -401,265,000
Net Income Past Year 673,725,000
Net Income Prior Year -352,088,000
Quarterly Revenue Growth YOY 43.70%
5-Year Revenue Growth -20.91%
Operating Margin Twelve Trailing Months -907.00%

Balance Sheet
Total Cash Most Recent Quarter 92,710,000
Total Cash Past Year 76,247,000
Total Cash Prior Year 88,205,000
Net Cash Position Most Recent Quarter 92,710,000
Net Cash Position Past Year 76,247,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 1,540,956,000
Total Stockholder Equity Prior Year 811,019,000
Total Stockholder Equity Most Recent Quarter 1,284,330,000

Free Cash Flow
Free Cash Flow Twelve Trailing Months -414,094,000
Free Cash Flow Per Share Twelve Trailing Months -7.10
Free Cash Flow Past Year -391,526,000
Free Cash Flow Prior Year -297,061,000

Options
Put/Call Ratio 0.19
Has Options Options Chain
Liquidity Rating

Technical Analysis
Yahoo Finance Chart Yahoo Finance Chart
MACD 0.00
MACD Signal 0.00
20-Day Bollinger Lower Band 0.00
20-Day Bollinger Middle Band 0.00
20-Day Bollinger Upper Band 0.00
Beta 0.86
RSI 0.00
50-Day SMA 34.14
150-Day SMA 32.82
200-Day SMA 31.29

System
Modified 12/22/2025 4:42:18 PM EST